Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab

OBJECTIVE: Patients with HER2-positive metastatic breast cancer (MBC) benefit from trastuzumab-based therapy but eventually develop intrinsic or acquired resistance. Whether plasma HER2 gene copy number (GCN) could predict survival after trastuzumab treatment remained controversial. We evaluated the...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Onco Targets Ther
Главные авторы: Ran, Ran, Huang, Wenfa, Liu, Yaxin, Shao, Lin, Liu, Xiaoran, Niu, Yunyun, Kong, Weiyao, Bo, Shiping, Rugo, Hope S, Lu, Sijia, Li, Huiping
Формат: Artigo
Язык:Inglês
Опубликовано: Dove 2020
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7245474/
https://ncbi.nlm.nih.gov/pubmed/32547071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S240990
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы